S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
Netflix Q4 Results, Now Its Time To Be Scared
Materials Sector Stock Winners: Consider These 3 in 2022
3 Mid-Cap Biotechs Analysts Think Can Double
3 Super Regional Banks That Look Super Charged After Earnings
Shares Of Union Pacific Are About To Leave The Station 
Intel building $20B Ohio chip facility amid global shortage
Yext Stock is a Quickly Becoming a Bargain Play
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
Netflix Q4 Results, Now Its Time To Be Scared
Materials Sector Stock Winners: Consider These 3 in 2022
3 Mid-Cap Biotechs Analysts Think Can Double
3 Super Regional Banks That Look Super Charged After Earnings
Shares Of Union Pacific Are About To Leave The Station 
Intel building $20B Ohio chip facility amid global shortage
Yext Stock is a Quickly Becoming a Bargain Play
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
Netflix Q4 Results, Now Its Time To Be Scared
Materials Sector Stock Winners: Consider These 3 in 2022
3 Mid-Cap Biotechs Analysts Think Can Double
3 Super Regional Banks That Look Super Charged After Earnings
Shares Of Union Pacific Are About To Leave The Station 
Intel building $20B Ohio chip facility amid global shortage
Yext Stock is a Quickly Becoming a Bargain Play
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
Netflix Q4 Results, Now Its Time To Be Scared
Materials Sector Stock Winners: Consider These 3 in 2022
3 Mid-Cap Biotechs Analysts Think Can Double
3 Super Regional Banks That Look Super Charged After Earnings
Shares Of Union Pacific Are About To Leave The Station 
Intel building $20B Ohio chip facility amid global shortage
Yext Stock is a Quickly Becoming a Bargain Play

Leede Jones Gab Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Leede Jones Gab. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Leede Jones Gab.

United States flag
MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
Export to Excel
CompanyDateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
CRDL
Cardiol Therapeutics
8/24/2021Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyHigh
QIPT
Quipt Home Medical
6/2/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyLow
LMNL
Liminal BioSciences
3/26/2021Reiterated byLeede Jones GabAnalyst D. LoeHoldLow
IMV
IMV
3/18/2021Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyHigh
PROF
Profound Medical
3/4/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyMedium
THTX
Theratechnologies
2/26/2021Downgraded byLeede Jones GabAnalyst D. LoeSpeculative Buy -> HoldLow
ONCY
Oncolytics Biotech
2/24/2021Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyHigh

MarketBeat Community Rating for Leede Jones Gab

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about Leede Jones Gab and other research firms. Vote "Outperform" if you believe Leede Jones Gab's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Leede Jones Gab's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.
See Also:

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.